Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus chemotherapy versus chemotherapy with or without nivolumab as first-line treatment for HER2-negative unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20262851Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Sep 2026; status: active.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20262851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262851.